Literature DB >> 23622858

Granulocyte transfusion therapy in paediatric patients with severe neutropenic infection.

Seda Oztürkmen1, Fevzi Altuntaş, Lale Olcay.   

Abstract

The data of 10 children who developed 13 high-risk febrile neutropenia with/without microbiologically documented severe infection, while being treated for a hematologic disorder were investigated retrospectively. The 24th hour post-transfusion neutrophil and platelet counts increased significantly, compared to the baseline values (p=0.034, p=0.025). Except three granulocyte transfusions (GTs) after which oliguria and/or mild respiratory distress developed, the transfusions were well tolerated. The clinical response, hematologic response and infection related mortality rates were 69.2%, 53.8% and 30.8%, respectively. Although our study includes limited number of patients, we can conclude that GT seems beneficial for children with severe sepsis during neutropenia.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23622858     DOI: 10.1016/j.transci.2013.04.022

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  4 in total

1.  Granulocyte Transfusion Therapy in Childhood.

Authors:  Elif Aktekin; Ali Bay; Mehmet Yılmaz
Journal:  Indian J Hematol Blood Transfus       Date:  2016-10-21       Impact factor: 0.900

Review 2.  Granulocyte transfusions in the management of invasive fungal infections.

Authors:  Kamille A West; Juan Gea-Banacloche; David Stroncek; Sameer S Kadri
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

3.  Role of granulocyte transfusions in combating life-threatening infections in patients with severe neutropenia: Experience from a tertiary care centre in North India.

Authors:  Akanksha Garg; Anshul Gupta; Ashish Mishra; Manoj Singh; Sanjeev Yadav; Soniya Nityanand
Journal:  PLoS One       Date:  2018-12-27       Impact factor: 3.240

Review 4.  Granulocyte transfusions in children and adults with hematological malignancies: benefits and controversies.

Authors:  Chiara Cugno; Sara Deola; Perla Filippini; David F Stroncek; Sergio Rutella
Journal:  J Transl Med       Date:  2015-11-16       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.